Immune check-point in endometrial cancer

被引：35
|
作者：
De Felice, Francesca [1 ]
Marchetti, Claudia [2 ]
Tombolini, Vincenzo [1 ]
Panici, P. Benedetti [3 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Viale Regina Elena 326, I-00161 Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy
[3] Sapienza Univ Rome, Dept Gynecol Obstet Sci & Urol Sci, Rome, Italy
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 08期
关键词：
Endometrial cancer; Immunotherapy; Immune check-point; Survival; Microsatellite instability; Mismatch repair; MISMATCH REPAIR STATUS; WOMEN; BLOCKADE; TUMORS; PEMBROLIZUMAB; ASSOCIATION; CARCINOMAS; EXPRESSION; OUTCOMES; PD-1;
D O I：
10.1007/s10147-019-01437-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors. Methods Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles. Results Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status. Conclusions Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.
引用
收藏
页码：910 / 916
页数：7
相关论文
共 50 条
  • [41] Chemotherapy and immune check point inhibitors in the management of cervical cancer
    Kumar, Lalit
    Upadhyay, Avinash
    Jayaraj, Aarthi S.
    CURRENT PROBLEMS IN CANCER, 2022, 46 (06)
  • [42] POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
    van Gool, Inge C.
    Eggink, Florine A.
    Freeman-Mills, Luke
    Stelloo, Ellen
    Marchi, Emanuele
    de Bruyn, Marco
    Palles, Claire
    Nout, Remi A.
    de Kroon, Cor D.
    Osse, Elisabeth M.
    Klenerman, Paul
    Creutzberg, Carien L.
    Tomlinson, Ian P. M.
    Smit, Vincent T. H. B. M.
    Nijman, Hans W.
    Bosse, Tjalling
    Church, David N.
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3347 - 3355
  • [43] Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade
    Zhou, Jun
    Li, Jingjing
    Guleria, Indira
    Chen, Tianqi
    Giobbie-Hurder, Anita
    Stevens, Jonathan
    Gupta, Meghna
    Wu, Xinqi
    Brennick, Ryan C.
    Manos, Michael P.
    Hodi, F. Stephen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (08) : 1331 - 1340
  • [44] Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer
    Zhou, Hongyu
    Chen, Lihua
    Lei, Yajie
    Li, Tianjiao
    Li, Haoran
    Cheng, Xi
    CURRENT PROBLEMS IN CANCER, 2021, 45 (02)
  • [45] Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
    Seya, Tsukasa
    Takeda, Yohei
    Takashima, Ken
    Yoshida, Sumit
    Azuma, Masahiro
    Matsumoto, Misako
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2018, 94 (03): : 153 - 160
  • [46] Lynch syndrome and endometrial cancer
    Bats, Anne-Sophie
    Rossi, Lea
    Le Frere-Belda, Marie-Aude
    Narjoz, Celine
    Cournou, Caroline
    Gosset, Marie
    Ngo, Charlotte
    Delomenie, Myriam
    Nos, Claude
    Blons, Helene
    Laurent-Puig, Pierre
    Lecuru, Fabrice
    BULLETIN DU CANCER, 2017, 104 (12) : 1013 - 1021
  • [47] Targeted therapy of ovarian cancer including immune check point inhibitor
    Kim, Jin Young
    Cho, Chi Heum
    Song, Hong Suk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (05): : 798 - 804
  • [48] Does MMR status in endometrial cancer influence response to adjuvant therapy?
    Kim, Soyoun Rachel
    Pina, Annick
    Albert, Arianne
    McAlpine, Jessica
    Wolber, Robert
    Gilks, C. Blake
    Kwon, Janice S.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 76 - 81
  • [49] First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function
    Myers, Jamie S.
    Parks, Adam C.
    Mahnken, Jonathan D.
    Young, Kate J.
    Pathak, Harsh B.
    Puri, Rajni V.
    Unrein, Amber
    Switzer, Phyllis
    Abdulateef, Yazan
    Sullivan, Samantha
    Walker, John F.
    Streeter, David
    Burns, Jeffrey M.
    CANCERS, 2023, 15 (05)
  • [50] Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
    Byeon, S.
    Cho, H. J.
    Jang, K-T
    Kwon, M.
    Lee, J.
    Kim, S. T.
    ESMO OPEN, 2021, 6 (01)
12345